Business Insight & People News
Pharmaceutical Preparations
Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.
Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.
Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.
Everyone below has filed at least one insider report against this company.
Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.
| Insider | Reported role | Shares | Value | Last action |
|---|---|---|---|---|
| Daniel A. Ninivaggi | Board Member | 20,645 | Not available | A Grant or award May 13, 2026 position reported |
| David E Wheadon | Board Member | 20,350 | Not available | A Grant or award May 13, 2026 position reported |
The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.
A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.
| Date | Insider | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 13, 2026 | David E Wheadon | A Grant or award | 10,430 | $0.00 | $0 | SEC filing ↗ |
| May 13, 2026 | Daniel A. Ninivaggi | A Grant or award | 6,518 | $0.00 | $0 | SEC filing ↗ |
| Jan 26, 2026 | David E Wheadon | A Grant or award | 5,955 | $0.00 | $0 | SEC filing ↗ |
| Jan 26, 2026 | Daniel A. Ninivaggi | A Grant or award | 3,722 | $0.00 | $0 | SEC filing ↗ |
| Jan 5, 2026 | David E Wheadon | P Open-market purchase | 1,771 | $35.39 | $62.7K | SEC filing ↗ |
| Jan 5, 2026 | Daniel A. Ninivaggi | P Open-market purchase | 775 | $35.39 | $27.4K | SEC filing ↗ |
From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.
The report an officer, director or large shareholder must file after trading their own company’s stock.
31 legal entities named in the subsidiary exhibit filed with this company’s most recent 10-K. . Filing on SEC.gov.
This is not the full list. SEC rules only require a company to name its significant subsidiaries.
Smaller entities are left out of the exhibit entirely. A short list here means a short exhibit — it does not mean the company owns nothing else. Nothing on this page is inferred: every name below is copied from the filing.
| Subsidiary | Organised in |
|---|---|
| Indivior Canada Ltd | Canada |
| Indivior Deutschland GmbH | Germany |
| Indivior España S.L.U. | Spain |
| Indivior EU Limited | England and Wales |
| Indivior Europe Limited | Ireland |
| Indivior Finance (2014) LLC | Delaware (US) |
| Indivior Finance LLC | Delaware (US) |
| Indivior France SAS | France |
| Indivior Global Holdings Limited | England and Wales |
| Indivior Inc. | Delaware (US) |
| Indivior Israel Ltd | Israel |
| Indivior Italia S.r.l | Italy |
| Indivior Jersey Finance (2021) Limited | Jersey |
| Indivior Jersey Finance LLC | Delaware (US) |
| Indivior Limited | England and Wales (as of January 26, 2026). |
| Indivior Manufacturing LLC | Delaware (US) |
| Indivior Nordics ApS | Denmark |
| Indivior Pty Ltd | Australia |
| Indivior Schweiz AG | Switzerland |
| Indivior SMTM LLC | Delaware (US) |
| Indivior Solutions Inc. | Delaware (US) |
| Indivior South Africa (Pty) Ltd | South Africa |
| Indivior Treatment Services, Inc. | Delaware (US) |
| Indivior UK Finance No1 Limited | England and Wales |
| Indivior UK Finance No2 Limited | England and Wales |
| Indivior UK Finance No3 Limited | England and Wales |
| Indivior UK Limited | England and Wales |
| Indivior US Holdings Inc. | Delaware (US) |
| Indy 1 (UK) Limited | England and Wales |
| Opiant Pharmaceuticals UK Limited | England and Wales |
| RBP Global Holdings Limited | England and Wales |
A subsidiary is a separate legal entity this company controls; it is not the same thing as a brand, a division or an office. These entities do not file with the SEC in their own right, so there is no separate page to open for them.
Think a number here is wrong? Open the linked filing and compare — how to report it.
Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.